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Accumulating evidence points to a key role of the
ubiquitin–proteasome pathway in oncogenesis. Aberrant
proteolysis of substrates involved in cellular processes such
as the cell division cycle, gene transcription, the DNA
damage response and apoptosis has been reported to
contribute signiﬁcantly to neoplastic transformation.
Cullin-dependent ubiquitin ligases (CDLs) form a class
of structurally related multisubunit enzymes central to the
ubiquitin-mediated proteolysis of many important biolo-
gical substrates. In this review, we describe the role of
CDLs in the ubiquitinylation of cancer-related substrates
and discuss how altered ubiquitinylation by CDLs may
contribute to tumor development.
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Introduction
The cellular abundance of many proto-oncoproteins and
tumor suppressors is controlled by the ubiquitin–
proteasome degradation pathway (Bashir and Pagano,
2003). Ubiquitin conjugation to a protein substrate
requires a two-step reaction catalysed by sequential
ubiquitin transferase enzymes. The ﬁrst enzyme, E1,
activates the entire pool of cellular ubiquitin proteins by
forming high-energy, unstable thiolester bonds with
ubiquitin (Hershko and Ciechanover, 1998). The second
transferase enzyme is one of many ubiquitin conjugating
enzymes (E2s or Ubcs), which covalently binds the
ubiquitin moiety to the substrate. Multiple rounds of
ubiquitin conjugations induce the polyubiquitinylation
of the substrate, which is then targeted for degradation
by the proteasome. A third class of enzymes, the
ubiquitin ligases (E3s), determines the speciﬁcity of the
reaction by simultaneously recognizing and directly
associating with speciﬁc substrates and binding and
positioning the E2 for ubiquitin conjugation to the
substrate. Cullin-dependent ubiquitin ligases (CDLs) are
one large class of E3s. These multisubunit ubiquitin
ligases always contain two core components: a cullin
subunit and a RING ﬁnger protein that stabilizes the
E2–cullin interaction.
Cullins
The name cullin derives from the fact that each member
of this family ‘culls’ or sorts different substrates for
ubiquitinylation (Kipreos et al., 1996). Budding yeast
have three cullin proteins: CulA (also known as Cdc53
or Cul1), CulB (also known as Cul3) and CulC (also
known as Cul8). Metazoans have at least ﬁve cullins
(Cul1–5). Sequence homology extends across the whole
length of Cul1–5, but it is greatest at the C-terminus that
contains a so-called ‘cullin domain’. Cullins derived
from successive duplication events of an ancestral cullin
gene that gave rise to two main branches: CUL1/2/5 and
CUL3/4. Caenorhabditis elegans cul6 (missing in verte-
brates) appears to have arisen by a duplication event of
the ancestral CUL1 gene, while a later duplication
separated mammalian CUL4A and CUL4B. An addi-
tional cullin member, Cul7, has been identiﬁed in
humans (Dias et al., 2002; Arai et al., 2003); however,
the homology is mostly in the cullin domain at the C-
terminus. At least three additional cullin domain-
containing proteins exist in mammals: KIAA0708 (Dias
et al., 2002); Parc, which interacts with the tumor
suppressor p53 controlling its subcellular localization
(Nikolaev et al., 2003); and Apc2, a subunit of another
E3 ubiquitin ligase – the anaphase promoting complex/
cyclosome (APC/C) (Yu et al., 1998a). Most cullin
members have been shown to associate with a RING
ﬁnger protein (Figure 1). Cul1–7 interact with either
Roc1 (also known as Rbx1) or the related Roc2 (Ohta
et al., 1999), while Apc2 interacts with Apc11, another
homolog of Roc1–2. The cullin–RING ﬁnger protein
complex contains intrinsic ubiquitin ligase activity in
vitro since puriﬁed recombinant cullin–Roc complexes
are able to catalyse substrate-independent ubiquitin
ligation by E2s, forming free ubiquitin chains. Similarly,
Parc contains two RING domains that are likely
responsible for its intrinsic substrate-independent
ubiquitin ligation activity (Nikolaev et al., 2003).
CDLs are positively regulated by covalent conjuga-
tion of the Nedd8 ubiquitin-like protein to a speciﬁc
lysine residue present in the cullin subunit (Hori et al.,
1999). Conversely, deconjugation of Nedd8 from cullins
by the isopeptidase activity of the COP9 signalosome
inhibits their ubiquitin ligase activity (Schwechheimer
and Deng, 2001). Despite the importance of the Nedd8
conjugation in modulating CDL functions, the signals
that regulate cullin neddylation remain elusive. Rather,
Nedd8 modiﬁcation of cullins appears to be a constitu-
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tive process that ensures the dynamic activity of CDLs
by allowing cycles of assembly and disassembly of
different substrate receptor subunits from CDLs.
The best-characterized mammalian cullin family
member is Cul1, which is a component of a multiprotein
ubiquitin ligase complex referred to as SCF (Skp1–
Cul1–F box protein) or Cdl1 (Figure 1) (Feldman et al.,
1997; Skowyra et al., 1997). In this complex, Cul1 acts as
a molecular scaffold simultaneously interacting at the
N-terminus with the adaptor subunit Skp1 and at the C-
terminus with Roc1 or 2 and a speciﬁc ubiquitin
conjugating enzyme (Ubc3, Ubc4 or Ubc5). Skp1, in
turn, binds to one of many members of a family of F
box proteins (FBPs) so named because they contain a
40-amino-acid motif called an ‘F box’ that is necessary
to bind to Skp1 (Cenciarelli et al., 1999; Winston et al.,
1999a; Kipreos and Pagano, 2000) (Figure 2). Each FBP
can be matched with a discrete number of speciﬁc
substrates through a protein–protein interaction domain
(WD-40 domains, leucine-rich repeats, etc.). Thus, the
substrate speciﬁcity of SCF complexes relies on the
availability of a large number of FBPs (11 in yeast, 326
in worms, 29 in ﬂy and approximately 70 in humans)
each targeting speciﬁc substrates for degradation.
Complexes similar to SCF ligases are formed by
analogous modular proteins that assemble to constitute
different CDLs. Cul7, like Cul1, assembles an SCF-like
E3 ubiquitin ligase (Cdl7) containing Roc1, Skp1 and
the FBP Fbw6 (Dias et al., 2002). In contrast to Cul1,
which can interact with Skp1 by itself, Cul7 is not
capable of binding to Skp1 unless it is in complex with
Fbw6, suggesting that Cdl7 cannot assemble with most
FBPs. Also C. elegans Cul6 may function in SCF
complexes since, like Cul1, it is able to interact with
Skr3, an Skp1-related protein (Nayak et al., 2002).
Interestingly, the fact that no Cul6 and Skr orthologs
have been identiﬁed in mammals so far, together with
the high number of FBPs present in C. elegans, suggests
that the Skr, cullin and FBP families underwent a
process of gene expansion speciﬁc for nematode devel-
opment and physiology.
Both Cul2 and Cul5 are able to assemble in a complex
(called Cdl2 and Cdl5, respectively) composed of a Roc
protein, Elongin B, Elongin C, and one of many SOCS
box proteins (SBPs), where SOCS stands for suppressor
of cytokine signaling (Kamura et al., 1998; Schoenfeld
et al., 2000; Kamura et al., 2001) (Figure 1). Cdl2 and
Cdl5 resemble the SCF complex, since sequence homo-
logies have been identiﬁed between Skp1 and Elongin C,
which are both adaptors for the substrate targeting
subunit, and between the FBP and the SBP. SBPs,
similarly to FBPs, constitute a large family of proteins
that contains protein–protein interaction domains used
to bind speciﬁc substrates (Hilton et al., 1998). Thus, as
for the SCF complexes, a common core (either Elongin
C–Elongin B–Cul2–Roc or Elongin C–Elongin B–Cul5–
Roc) can be coupled to a large number of substrates
through different and numerous SBPs. In addition, Cdl2
and Cdl5 can contain other substrate receptors that do
not have a clear SOCS box but a more loose motif called
a ‘BC box’ since it is necessary to bind to Elongin B and
C (Kamura et al., 1998). However, it is likely that not all
of the large number of BC box-containing proteins
(BCBPs) identiﬁable in a computer analysis are indeed
components of Cdl2 and Cdl5.
Genetic and biochemical approaches show that Cul3
is also a subunit of a modular ubiquitin ligase system
(Cdl3) (Furukawa et al., 2003; Geyer et al., 2003;
Pintard et al., 2003; Xu et al., 2003). In the attempt to
identify the adaptor protein equivalent to Skp1 that
plays a conserved function in the Cdl3 complex, C.
elegans Cul3 was used as a bait in a yeast two-hybrid
screen (Xu et al., 2003). In all, 11 Cul3-speciﬁc
interactors were isolated. All have a common domain,
previously termed broad-complex, Tramtrack and Bric-
a-Brac (BTB), which is thought to play a role in protein–
protein interaction (Zollman et al., 1994; Chen et al.,
1995). BTB proteins (BTBPs) from different species can
contain additional domains that are also known to
mediate protein–protein interaction such as MATH
domains, kelch repeats, WD40 repeats and Zn-ﬁnger
repeats. Remarkably, the structure of Skp1 and the BTB
domain of human promyelocytic leukemia zinc-ﬁnger
(PLZF) protein revealed the presence of conserved
structural features. Moreover, both Skp1 and BTBPs
bind to a common interface in Cul1 and Cul3,
respectively. These ﬁndings suggest that BTBPs might
represent a common component of Cul3-dependent
ubiquitin ligases (Figure 1). Each BTBP might act as
the equivalent of the Skp1–FBP complex characteristic
of the SCF. Indeed, BTBPs bind to Cul3 (as Skp1 to
Cul1) and at the same time to a substrate (as the FBP).
It is also possible that those BTBPs that lack other
protein–protein interaction domains might associate
Figure 1 CDLs are composed of analogous modular proteins that assemble to form multiprotein complexes with ubiquitin ligase
activity. See text for details
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with additional adaptor proteins that in turn recognize
speciﬁc targets.
Finally, Cul4 is also part of a complex with ubiquitin
ligase activity (Chen et al., 2001; Nag et al., 2001). The
ﬁnding that Cul4A associates with Roc1 and Damaged
DNA-Binding proteins (DDB) to mediate the cellular
response to DNA damage suggests that Cul4 is part of a
multiprotein complex whose ubiquitin ligase activity
plays an important part in tumorigenesis (Groisman
et al., 2003) (Figure 1).
Since about 70 FBPs (Cenciarelli et al., 1999; Winston
et al., 1999a; Kipreos and Pagano, 2000), 40 SBPs
(Hilton et al., 1998; Kile et al., 2002) and 190 BTBPs
(Zollman et al., 1994) have been identiﬁed in mammals,
the cullin family appears to control the ubiquitinylation
of a large number of cellular substrates. This review
aims to summarize the current knowledge regarding
oncogenic aberration of speciﬁc CDLs and some of their
substrates, focusing particularly on Cul1–5.
Cdl1: the SCF complex
Cul1, the ortholog of yeast Cdc53, was the ﬁrst member
of the cullin family to be identiﬁed in metazoans
(Kipreos et al., 1996). In C. elegans, loss-of-function
mutations of CUL1 lead to hyperplasia of all tissues
with a shortened G1phase of the cell cycle. Moreover,
Cul1 is necessary for proper cell cycle exit. In mice,
loss of Cul1 results in early embryonic lethality (Dealy
et al., 1999; Wang et al., 1999). Cul1-deﬁcient embryos
implant in the uterine wall but do not develop beyond
embryonic day 5.5, before the onset of gastrulation. In
addition, apoptosis is increased in the embryonic
ectoderm. The early lethality in Cul1-deﬁcient mice is
likely due to the accumulation of a large number of
substrates targeted by the SCF ubiquitin ligases. Since
the FBP family has approximately 70 members, about
70 SCF complexes are expected to be present in
mammalian cells, but only three of them have been
extensively studied and matched with their correspon-
dent substrates: SCFSkp2, SCFFbw7 and SCFb-Trcp.
SCFSkp2
Three groups have independently demonstrated a role
for SCFSkp2 in the degradation of the cyclin-dependent
kinase (CDK) inhibitor p27Kip1 (Carrano et al., 1999;
Marti et al., 1999; Tsvetkov et al., 1999). Skp2 interacts
with p27, an association that requires phosphorylation
of p27 on threonine 187 by CDKs. Ligation of
phosphorylated p27 to ubiquitin can be reconstituted
in vitro using puriﬁed components of the SCFSkp2
complex (Ganoth et al., 2001). In this context, it was
demonstrated that SCFSkp2 requires an accessory pro-
tein, known as CDK subunit 1 (Cks1), for its ubiquitin
ligase activity toward phosphorylated p27 (Ganoth et al.,
2001; Spruck et al., 2001). In vivo expression of an F
box-deleted Skp2 mutant, which acts as a dominant-
negative mutant because it is unable to bind the Skp1–
Cul1–Roc1 complex but is still capable of binding p27,
Figure 2 Three SCF complexes, SCFSkp2, SCFFbw7 and SCFb-Trcp, contain a common core, composed of Cul1, Skp1 and Roc1, that
associates with different FBPs. Each FBP acts as a substrate receptor subunit that is coupled to a discrete number of speciﬁc
phosphorylated (indicated in the ﬁgure with a ‘P’) substrates through protein–protein interaction domains. The most extensively
characterized substrates for these SCF ligases are shown
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increases p27 stability. Accordingly, Skp2 knockdown
by RNA interference or by using antisense oligonucleo-
tides induces stabilization of p27. In addition, targeted
inactivation of the mouse Skp2 locus by homologous
recombination results in accumulation of p27 (Nakaya-
ma et al., 2000). Skp2-deﬁcient mice are viable, with no
gross anatomic abnormalities, but their body weight is
two-thirds of that of their littermate controls. The small
size phenotype of the Skp2 knockout mice is the
opposite of the phenotype of the p27/ mice, which
are abnormally large. Moreover, Skp2-deﬁcient ﬁbro-
blasts show a reduced growth rate and centrosome
overduplication. Skp2/ hepatocytes have enlarged
and polyploid nuclei. Similar abnormalities were found
in the kidney, lung, testis and mouse embryonic
ﬁbroblasts (MEFs), whereas they are absent in all the
other organs analysed. Remarkably, most of the cellular
and histopathological defects observed in Skp2-deﬁcient
mice are suppressed in Skp2/;p27/ mice, impli-
cating p27 as a major substrate for Skp2 (K Nakayama,
personal communication) (Figure 2).
It has been proposed that SCFSkp2 controls the
degradation of two other CDK inhibitors, p21Cip1 and
p57Kip2, during the S phase of the cell cycle (Bornstein
et al., 2003; Kamura et al., 2003). In fact, p21 and p57
are efﬁciently ubiquitinylated by the SCFSkp2 ubiquitin
ligase complex in vitro and their rate of degradation is
much slower in Skp2-deﬁcient ﬁbroblasts synchronized
in S phase than in wild-type cells. Signiﬁcantly, both p21
and p57 stabilization also occurs in Skp2/;p27/
cells, ruling out the possibility that their accumulation
could be caused indirectly by the increased percentage of
cells in the G0/G1phase of the cell cycle resulting from
elevated levels of p27. The fact that both p21 and p57
are still degraded in G0/G1 even in the absence of Skp2
indicates that more than one system cooperates to
regulate the turnover of these two CDK inhibitors.
SCFSkp2 also has a role in the degradation of the
retinoblastoma-related ‘pocket’ protein p130 (Tedesco
et al., 2002). The levels of p130 protein are regulated
through the cell cycle, being maximal in G0/G1 and then
decreasing as cells enter S phase despite the fact that
the levels of p130 mRNA do not change signiﬁcantly
during the cell cycle. SCFSkp2 is responsible for this
regulation by binding to p130 and mediating its
ubiquitinylation. This interaction is phosphorylation
dependent since phosphorylation of serine 672 is
necessary for Skp2 binding and p130 destruction.
Importantly, p130 accumulates in thymidine-arrested
Skp2/ MEFs conﬁrming that p130 is a substrate of
SCFSkp2 in S phase.
It has been reported that during the G1 to S transition
of the cell cycle, Skp2 regulates the ubiquitinylation and
stability of the transcription factor c-Myc, an oncopro-
tein that plays a major role in oncogenesis (Kim et al.,
2003; von der Lehr et al., 2003). Surprisingly, Skp2
enhances c-Myc-induced S phase transition and acti-
vates c-Myc transcriptional activity. In fact, Skp2
overexpression was shown to induce the transcription
of c-Myc target genes suggesting that Skp2 acts as a
transcription coactivator of c-Myc. These results in-
dicate that Skp2 can concurrently lead to degradation of
tumor suppressors (p27, p57, p21 and p130) and to
activation of an oncogene (c-Myc). While Skp2-deﬁcient
mice, which should have decreased c-Myc activity, can
develop almost normally (Nakayama et al., 2000), c-
Myc knockout mice die in utero between 9.5 and 10.5
days of gestation with severe abnormalities affecting the
heart, pericardium and neural tube (Davis et al., 1993).
One would naively expect that, in vivo, inactivation of
Skp2 would compromise c-Myc function and result in a
more severe phenotype. In addition, the mechanism by
which ubiquitinylation can activate gene transcription
and subsequently decrease protein stability is still
unclear.
Other cancer-related substrates have been described
to be degraded by SCFSkp2. Li et al. (2003) found that the
ubiquitinylation and degradation of the replication
licensing factor Cdt1 is mediated by SCFSkp2. Kiernan
et al. (2001) proposed a mechanism in which Cyclin T1
recruits the cyclin-dependent kinase Cdk9 to SCFSkp2
leading to its ubiquitinylation and destruction. How-
ever, the role of SCFSkp2 in the regulation of Cdk9 is not
yet well deﬁned since a more recent study showed that
Cdk9 is a stable protein that is not affected by Skp2
overexpression or downregulation, suggesting that
Skp2/Cdk9 interaction has a physiological signiﬁcance
different from protein degradation (Garriga et al.,
2003). Mendez et al. (2002) found that the origin
replication factor Orc1 is ubiquitinylated and degraded
on chromatin via Skp2. Charrasse et al. (2000) reported
that Skp2 interacts with the oncoprotein B-Myb
stimulating its degradation. Marti et al. (1999) reported
that the transcription factor E2F1 is able to bind Skp2
and Cul1, and that mutations in the E2F1 N-terminal
region that abolish binding to Skp2 decrease E2F1
ubiquitinylation and lead to its stabilization. Moreover,
Skp2 seems to play a role in the ubiquitinylation and
degradation of Cyclin D1 and Cyclin E. Cyclin D1,
which is overexpressed in several human tumors, is
ubiquitinylated and degraded by the proteasome, and
some lines of evidence indicate that Skp2 might be
implicated, at least in part, in this process (Yu et al.,
1998b; Ganiatsas et al., 2001). Finally, Nakayama et al.
(2000) found that Skp2 can bind to the CDK-unbound,
inactive form of Cyclin E and mediate its ubiquitinyla-
tion. Skp2 interaction with Cyclin E seems to be
independent of Cyclin E phosphorylation. Moreover,
accumulation of free Cyclin E is not a secondary effect
due to the elevated levels of p27 since it occurs also in
Skp2/;p27/ MEFs (K Nakayama, personal com-
munication). All these studies implicate SCFSkp2 in the
ubiquitinylation of numerous substrates. Notably,
Skp2/ MEFs display an accumulation of p27, p21,
p130, p57 and unphosphorylated, inactive Cyclin E,
while no stabilization of Cyclin D1 and E2F1 has been
observed (Nakayama et al., 2000; Tedesco et al., 2002;
Bornstein et al., 2003). The turnover of Orc1, Cdt1, B-
Myb and c-Myc has not yet been investigated in Skp2-
deﬁcient cells.
The described role of Skp2 in inducing the ubiquiti-
nylation and degradation of the tumor suppressor p27,
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and more recently of p21, p57 and p130, indicates
that Skp2 may be the product of a proto-oncogene.
Several studies conﬁrm that Skp2 has oncogenic
properties. First, an inverse relationship between Skp2
and p27 protein levels was found in human lymphomas
(Latres et al., 2001; Chiarle et al., 2002), breast
carcinomas (Signoretti et al., 2002), epithelial dysplasias
(Gstaiger et al., 2001), colorectal carcinomas (Hershko
et al., 2001), oral squamous cell carcinomas (Kudo et al.,
2001), small cell lung cancers (Yokoi et al., 2002),
gastric carcinomas (Masuda et al., 2002) and prostate
cancers (Ben-Izhak et al., 2003). In addition, Skp2
expression signiﬁcantly and directly correlates with
tumor malignancy and aggressiveness, and is associated
with poor prognosis in human lymphomas (Latres et al.,
2001; Chiarle et al., 2002), prostate cancers (Ben-Izhak
et al., 2003) and ovarian adenocarcinomas (Shigemasa
et al., 2003). Moreover, Skp2 protein expression
increases during progression from epithelial dysplasia
to invasive carcinoma (Gstaiger et al., 2001). Impor-
tantly, frequent ampliﬁcation and overexpression of the
SKP2 gene has been observed in primary small cell lung
cancers (Yokoi et al., 2002), and in cell lines expressing
high-risk human papilloma virus (Dowen et al., 2003).
Similarly, Cks1 message has been found highly ex-
pressed in a subgroup of breast cancers (ER-negative
and Her-2-negative) (Signoretti et al., 2002), in hepato-
cellular carcinomas (Okabe et al., 2001), gastric adeno-
carcinomas (El-Rifai et al., 2001), epithelial ovarian
cancers (Welsh et al., 2001) and non-small cell lung
carcinomas (Inui et al., 2003). Accordingly, Cks1
protein levels are increased in colorectal carcinomas
(D Hershko and M Pagano, unpublished) and prostate
cancers (A Baron, M Loda and M Pagano, unpub-
lished). It has been reported that Skp2 and H-RasG12V
cooperatively transform primary rat ﬁbroblasts as
scored by colony formation in soft agar and tumor
formation in nude mice (Gstaiger et al., 2001). Finally,
ectopic expression of Skp2 in nonadherent ﬁbroblasts
leads to entry into S phase, p27 downregulation and cell
division, indicating that anchorage-dependent growth, a
characteristic of nontransformed cells, is abrogated by
Skp2 overexpression (Carrano and Pagano, 2001). Two
mouse models conﬁrm the oncogenic properties of
Skp2. In the ﬁrst one, targeted Skp2 expression to
the T-lymphoid lineage markedly cooperates with the
activated oncogene N-Ras (Latres et al., 2001). Com-
pared to transgenic animals expressing activated
N-Ras alone, Skp2 coexpression causes an acceleration
in tumor onset, increased penetrance of lymphomagen-
esis and decreased survival rate. Importantly, these
tumors contain decreased levels of p27 compared with
nontransformed cells. In the second mouse model,
enforced expression of Skp2 in the prostate gland
induces hyperplasia, dysplasia and low-grade carcinoma
accompanied by increased proliferation, downregulation
of p27 and high levels of mitotic markers such as Ki67
and Cyclin B1 (Shim et al., 2003). Thus, the mouse
models are in agreement with the results in human
tissues, conﬁrming a major role for Skp2 in tumor
development.
Using transgenic animal models it has been shown
that interference with Skp1 and Cul1 functions in vivo
leads to reduced cell proliferation and, after a period of
latency, to genetic instability and neoplastic transforma-
tion (Piva et al., 2002). Thus, the idea of targeting Cul1
or the Nedd8 pathway does not represent a valid
approach for the therapy of human diseases since it will
result in decreased cell proliferation, likely due to the
accumulation of substrates such as p27 and p21, but also
in devastating unwanted effects (i.e., malignant trans-
formation). In contrast, inhibition of Skp2 activity
results in a decreased malignant potential of cancer
cells since they show a reduced ability to grow in the
absence of cell adhesion (Signoretti et al., 2002) and no
longer proliferate when injected with an anti-Skp2
antibody (Zhang et al., 1995) or when transfected with
an Skp2 siRNA duplex (Bashir et al., 2004). In
conclusion, Skp2 inhibitors might represent a speciﬁc
and valid therapeutic option in epithelial tumors and
lymphomas.
SCFFbw7
Three groups have reported that Cyclin E ubiquitinyla-
tion is mediated by the ubiquitin ligase SCFFbw7 (Koepp
et al., 2001; Moberg et al., 2001; Strohmaier et al., 2001).
In a genetic screen to identify genes that restrain cell
proliferation, Hariharan’s group identiﬁed archipelago,
a gene encoding the Drosophila ortholog of the C.
elegans F box protein Sel-10 and human Fbw7 (Moberg
et al., 2001). Importantly, archipelago mutant cells
express higher levels of Cyclin E protein, but not
mRNA, compared with wild-type control cells. These
results, together with the direct physical interaction
between Archipelago and Cyclin E, suggested a role for
Archipelago in the degradation of Cyclin E. A different
genetic approach was used by Koepp et al. (2001) and
Strohmayer et al. (2001) to identify the speciﬁc SCF
ubiquitin ligase responsible for Cyclin E ubiquitinyla-
tion and degradation. In a stability assay in yeast, it was
found that Cyclin E is stabilized in CulA, Skp1 and
Cdc4 mutants. No difference in Cyclin E turnover was
detected in mutant strains for other yeast FBPs.
Moreover, Fbw7 (also called hCdc4) can partially rescue
the CDC4 mutation in yeast. To conﬁrm this speciﬁcity,
the binding of Cyclin E with different mammalian FBPs
was tested. Of these, only Fbw7 is able to associate
physically with Cyclin E. The interaction between Fbw7
and Cyclin E is phosphorylation dependent since
mutation on two residues phosphorylated by Cdk2
(threonine 62 and 380) impairs Cyclin E ability to bind
Fbw7. Furthermore, SCFFbw7 is able to ubiquitinylate
Cyclin E in a phosphorylation-dependent manner in
vitro. Thus, whereas the degradation of free, inactive
Cyclin E, via Skp2, occurs in a phosphorylation-
independent fashion, the degradation of active, Cdk2-
bound Cyclin E, via Fbw7, requires phosphorylation.
Finally, overexpression of Fbw7 leads to decreased
levels of Cyclin E, and, conversely, inhibition of Fbw7
by RNA interference causes accumulation of Cyclin E.
Taken together, these results demonstrate that SCFFbw7
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controls the stability of Cyclin E in mammalian cells and
that this role is well conserved through evolution.
Remarkably, one of the three alternative transcripts
of the FBW7 gene is induced by the tumor suppressor
p53 in response to genotoxic stresses caused by UV
irradiation and adriamycin treatment (Kimura et al.,
2003), suggesting that to arrest the cell cycle p53
might induce Cyclin E degradation via upregulation
of Fbw7.
Sel-10 (the worm name for Fbw7) was originally
identiﬁed as a negative regulator of the Notch pathway
in C. elegans. In addition, mammalian Fbw7 was shown
to target Notch1 and Notch4 for ubiquitin-dependent
degradation (Gupta-Rossi et al., 2001; Oberg et al.,
2001; Wu et al., 2001). The involvement of Fbw7 in the
control of the Notch pathway is conﬁrmed by the
ﬁnding that Notch4 accumulates in Fbw7-deﬁcient
embryos, which die in utero at embryonic day 10.5 and
manifest abnormal vascular development (K Nakaya-
ma, personal communication). In addition, Notch4
degradation is impaired in Fbw7/ cells. In contrast,
the expression of Notch1, Notch2 and Notch3 is
comparable among different genotypes. The ﬁnding
that Fbw7/ embryos exhibit severe defects in vascular
development is likely due to the upregulation of the
transcriptional repressor Hey-1, a downstream effector
of Notch signaling.
Fbw7 is also responsible for the degradation of
the oncoprotein c-Myc (B Clurman, I Hariharan and
K Nakayama, personal communication). This de-
gradation is phosphorylation dependent since
phosphorylation of threonine 58 is necessary for
c-Myc degradation.
The role of Fbw7 in the degradation of Cyclin E,
Notch and c-Myc suggests that it might function
as a tumor suppressor. Levels of Cyclin E are often
increased in ovarian and breast tumors (Keyomarsi
and Herliczek, 1997). Importantly, mutations of
FBW7 were found in three out of ten ovarian cancer
cell lines analysed, indicating that mutations of
FBW7 might be responsible for elevated levels of
Cyclin E in this tumor (Moberg et al., 2001). In
addition, one breast cancer cell line, SUM149PT,
that displays elevated levels of Cyclin E expresses an
Fbw7 mutant form encoding a protein lacking the
last four WD40 domains that are responsible
for binding to the substrates (Strohmaier et al.,
2001). Moreover, the human FBW7 gene is mutated
in 16% of primary endometrial adenocarcinomas,
and loss of heterozygosity (LOH) was detected in
most of these tumors (Spruck et al., 2002). It would
be interesting to analyse the levels c-Myc and Notch
in those human primary tumors where mutations
of FBW7 have been found. Preliminary studies
indicate that FBW7 mutations are often associated
with high tumor aggressiveness. FBW7 might be
mutated in other tumor types since chromosome
region 4q32, where FBW7 has been mapped, is
deleted in 67% of lung cancers, 63% of head and neck
cancers, 41% of testicular cancers and 27% of breast
cancers.
SCFb-Trcp
The mammalian SCFb-Trcp (b-transducin repeat-contain-
ing protein) has been implicated in the regulation of at
least two different signal transduction pathways, Wnt/
Wingless and NF-kB, by mediating the ubiquitinylation
and degradation of the transcriptional coactivator b-
catenin and the NF-kB inhibitor IkB, respectively
(Maniatis, 1999). Furthermore, b-Trcp controls cell
cycle progression by stimulating the degradation of
Emi1 (Early mitotic inhibitor 1) (Guardavaccaro et al.,
2003; Margottin-Goguet et al., 2003; Peters, 2003) and
Cdc25A (Busino et al., 2003). It has been shown that
additional substrates are degraded via b-Trcp-dependent
ubiquitinylation like the transcription factor ATF4/
CREB2 (Lassot et al., 2001), NF-kB/p105 (Orian et al.,
2000), NF-kB/p100 (Fong and Sun, 2002) and the discs
large (hDlg) tumor suppressor (Mantovani and
Banks, 2003). All these substrates share a common
motif, DSGxx(x)S, and they can be recognized by
b-Trcp once the two serine residues of this element are
phosphorylated. However, at least in non-mammalian
organisms, b-Trcp substrates that lack this motif have
been identiﬁed. In human and mouse cells, two closely
related paralogous b-Trcp gene products are
present, known as b-Trcp1 (or Fbw1A) and b-Trcp2
(also called Fbw1B or HOS). b-Trcp1 and b-Trcp2 are
ubiquitously expressed in both human and mouse
tissues (Cenciarelli et al., 1999; Koike et al., 2000;
Maruyama et al., 2001) and have similar biochemical
properties in their capability to mediate the ubiquitiny-
lation of their speciﬁc substrates. The function of
b-Trcp in the degradation of b-catenin and IkBa is
conserved through evolution since loss-of-function
mutations of slimb, the Drosophila ortholog of b-Trcp,
result in the accumulation of Armadillo, the Drosophila
ortholog of b-catenin (Jiang and Struhl, 1998), and
reduced expression of twist and snail, two downstream
targets of dorsal/NF-kB (Spencer et al., 1999). Slimb
mutations cause also a defective proteolytic processing
of Cubitus interruptus (Ci) and ectopic expression of
Hedgehog-responsive genes (Jiang and Struhl, 1998),
suggesting that Ci might be a substrate of Slimb. In
addition, it has been reported that Slimb is implicated in
the degradation of the circadian clock protein Period
(Ko et al., 2002). Finally, the C. elegans b-Trcp ortholog
lin-23 functions to regulate negatively cell cycle progres-
sion, since lin-23 null mutant cells undergo extra
divisions, generating supernumerary cells (Kipreos
et al., 2000).
Several groups have demonstrated a role for mam-
malian b-Trcp1 and b-Trcp2 in the ubiquitinylation of
b-catenin in vitro and in cultured cells (Hart et al., 1999;
Kitagawa et al., 1999; Latres et al., 1999; Winston et al.,
1999b). Under normal conditions, b-catenin associates
with the adenomatous polyposis coli (APC) tumor
suppressor, axin, and Gsk3b. In this complex, b-catenin
is constitutively phosphorylated by Gsk3b on the two
serine residues of the b-Trcp binding motif allowing the
binding of b-catenin to SCFb-Trcp and its subsequent
ubiquitinylation.
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CTNNB1 (the gene encoding b-catenin) and other
regulatory genes in this pathway are often mutated in
primary human cancers such as colorectal, hepatocel-
lular, desmoid, ovarian, endometrial, thyroid, prostate
tumors and malignant melanomas (Polakis, 1999, 2000).
In all the cases, the common consequence of these
mutations is b-catenin accumulation, its translocation
into the nucleus and transcriptional activation of target
genes such as c-Myc and Cyclin D. Several mutations in
CTNNB1 found in human tumors affect the speciﬁc
serine residues or the amino acids adjacent to them that
mediate the phosphorylation-dependent interaction of
b-catenin with b-Trcp (Polakis, 2000). b-catenin can be
oncogenically activated not only by direct mutation but
also by inactivation of APC. Alterations of the APC
gene occur in 80% of the human colon cancers. In the
absence of APC, b-catenin cannot be phosphorylated by
Gsk3b, and it consequently accumulates and translo-
cates into the nucleus (Polakis, 2000).
Degradation of b-catenin by b-Trcp suggests a role
for this FBP as a tumor suppressor gene, the alteration
of which may be found in human tumors. However, no
mutations in the BTRC gene (encoding b-Trcp1) or
BTRC2 (encoding b-Trcp2) have been found in colon
cancers wild type for CTNNB1 and APC. The only
reports showing genetic alterations of the BTRC genes
in human tumors are those by Saitoh and Katoh (2001)
and Gerstein et al. (2002). The ﬁrst group searched for
genetic alterations of BTRC2 in gastric cancer. One
nucleotide substitution was identiﬁed in OKAJIMA
cells, which leads to an amino-acid substitution in the
seventh WD40 repeat domain. In the second study, 22
samples including prostate tumor cell lines, xenographs
and primary prostate tumors were analysed. Two
alterations in BTRC were found, which are expected
to render the protein deﬁcient in b-catenin binding. In
this context, it is worth noting that disrupting the Btrc
locus in mice or silencing of either b-Trcp1 or b-Trcp2
alone in human cells is not sufﬁcient to induce
signiﬁcant defects in b-catenin degradation (Guarda-
vaccaro et al., 2003). Stabilization of b-catenin requires
instead the inactivation of both b-Trcp1 and b-Trcp2,
indicating that mutation of either BTRC or BTRC2
alone might not provide a substantial cell growth
advantage. Furthermore, given the role of b-Trcp in
the degradation of IkB proteins, it is possible that
inactivating mutations in BTRC are incompatible with
transformation because of an increase of apoptosis as a
result of NF-kB inhibition.
NF-kB is a transcription factor that is sequestered in
the cytoplasm by association with a member of a class of
NF-kB inhibitors called IkB proteins (Karin and Ben-
Neriah, 2000). In response to a variety of stimuli such as
extracellular signals, virus infection and ionizing radia-
tion, IkB proteins are phosphorylated by the IkB kinase
complex and degraded by the ubiquitin–proteasome
pathway, releasing NF-kB that, in turn, translocates
into the nucleus and activates the transcription of a large
number of target genes. In 1998 Ben-Neriah’s group,
using biochemical methods, identiﬁed b-Trcp1 as the
receptor component of the IkBa–ubiquitin ligase (Yaron
et al., 1998). Subsequently, other groups (Hatakeyama
et al., 1999; Hattori et al., 1999; Kroll et al., 1999;
Shirane et al., 1999; Spencer et al., 1999; Winston et al.,
1999b; Wu and Ghosh, 1999) provided additional strong
evidences that IkBa phosphorylation on the two serine
residues of the b-Trcp binding domain leads to IkBa
association with SCFb-Trcp1/2. The NF-kB transcription
factors are regulators of the immune response. They are
also implicated in the positive regulation of cell
proliferation and inhibition of apoptosis, and accumu-
lating evidence points to a role for NF-kB in neoplastic
transformation (Luque and Gelinas, 1997; Rayet and
Gelinas, 1999). Indeed, chromosomal aberrations and
various mutations in genes encoding NF-kB transcrip-
tion factors have been found in many different human
tumors such as lung, colon, breast, and prostate cancers,
Hodgkin’s lymphomas, Ewing sarcomas, pancreatic
carcinomas, familial medullary thyroid carcinomas and
nasopharyngeal carcinomas. Alterations decreasing the
expression and the function of IkB proteins have also
been observed in many cancers (Rayet and Gelinas,
1999). All these different aberrations lead to hyperacti-
vation of the NF-kB signaling pathway. Since many
studies have reported that NF-kB proteins can inhibit
apoptosis in response to a variety of stimuli, it is thought
that constitutive NF-kB activity contributes to tumor
development by promoting cell survival. The role of b-
Trcp in the ubiquitinylation of IkB proteins indicates
that b-Trcp could control the NF-kB-dependent apop-
totic pathway. Interestingly, it has been found that
inhibition of b-Trcp by overexpressing a dominant-
negative b-Trcp2 mutant sensitizes human melanoma
cell lines to apoptosis induced by cytokines, cisplatin,
ionizing radiation and UV irradiation (Soldatenkov
et al., 1999). Inhibition of b-Trcp renders cells more
susceptible to apoptotic cell death because of IkB
accumulation but likely also because of the stabilization
of other substrates, such as b-catenin, Emi1 and
Cdc25A, which could potentially push cells out of
quiescence, a state in which cells are more resistance to
apoptosis. Bhatia et al. (2002) found that the b-Trcp2
transcript is upregulated in chemically induced mouse
papillomas and squamous cell carcinomas and this
overexpression is associated with accelerated degrada-
tion of IkBa and constitutive activation of NF-kB.
Moreover, b-Trcp1 overexpression in mouse mammary
gland epithelium leads to increased ductal branch-
ing and elevated proliferation of the epithelial cells
correlating with enhanced NF-kB activity (Y Kudo,
D Guardavaccaro, P Gonzalez and M Pagano, unpub-
lished results). All together, these results raise the
possibility that inhibition of b-Trcp may augment the
therapeutic response of tumor cell death-inducing
protocols.
Recently, genetic and biochemical approaches have
revealed an unexpected role for SCFb-Trcp1 in the
regulation of both meiosis and mitosis (Guardavaccaro
et al., 2003). Inactivation of the Btrc gene in mice causes
a defective spermatogenesis with accumulation of
primary spermatocytes in metaphase and the appear-
ance of multinucleated spermatids. Moreover, a subset
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of Btrc-deﬁcient spermatocytes displays spindle ab-
normalities and misalignment of chromosomes. These
meiotic defects correspond to mitotic defects in somatic
cells. First, Btrc knockout mice develop tumors at low
incidence (unpublished results). In addition, MEFs
isolated from Btrc/ embryos progress more slowly
through mitosis if compared with wild-type cells. Btrc-
deﬁcient MEFs display centrosome overduplication,
multipolar metaphase spindles and misalignment of
chromosomes. Moreover, stabilization of Emi1 was
found both in Btrc/ MEFs and in HeLa cells in
which b-Trcp1 expression was silenced by RNA inter-
ference. It has been reported that Emi1 inhibits APC/C
activity thereby preventing destruction of mitotic cyclins
and other APC/C substrates like Securin, Aurora-A and
Nek2 (Peters, 2002). Emi1 contains a canonical DSGxxS
b-Trcp1 binding domain suggesting that it could be a
direct substrate of b-Trcp1. Several results validate this
hypothesis. Emi1 is able to bind b-Trcp1 both in vitro
and in vivo, and this binding depends on the presence of
the two serine residues of the b-Trcp binding domain.
Wild-type Emi1 is stabilized when overexpressed in
mitotic Btrc/ MEFs, and a mutant form of Emi1, in
which both serines have been mutated into alanine, is
stable in MEFs of both genotypes. In a cell-free assay
for Emi1 ubiquitinylation, Emi1-ubiquitin ligation
activity was found to be higher in the extract from
wild-type prometaphase MEFs than from Btrc/
prometaphase MEFs. Mutant Emi1 is not ubiquitiny-
lated by either extracts. Remarkably, the addition of
puriﬁed recombinant b-Trcp1 to the extract from Btrc/
 MEFs in prometaphase is able to rescue the defective
Emi1 ubiquitinylation. The levels of Emi1 transcript and
protein are upregulated in many human tumors, in
particular breast, lung, colon, uterus and ovary (Hsu
et al., 2002; van’t Veer et al., 2002). Emi1 degradation by
b-Trcp in early mitosis suggests a mechanism for how
Emi1 upregulation may contribute to genomic instabil-
ity. In fact, Emi1 accumulation leads to inhibition of
APC/C and subsequent overexpression of APC/C
substrates such as Cyclin A, Aurora-A and Securin
causing an error-prone mitosis (Reimann et al., 2001).
Finally, it has been recently found that b-Trcp targets
Cdc25A, a Cdk1 and Cdk2 activating phosphatase, for
degradation during S phase and in response to ionizing
radiation-induced DNA damage (Busino et al., 2003).
Cdc25A is able to interact with SCFb-Trcp1/2 through a b-
Trcp binding domain (DSGxxxxS) that is required for
Cdc25A ubiquitinylation and degradation. Silencing of
b-Trcp by RNA interference causes accumulation of
Cdc25A in the S phase of the cell cycle and Cdc25A
defective destruction in response to ionizing radiation,
indicating that b-Trcp has a role in the S phase
checkpoint.
Cul1 and Skp1 are localized on the centrosome and
play a key role in centriole splitting (Freed et al., 1999;
Gstaiger et al., 1999). Cul1 and Skp1 also control later
steps of the centrosome cycle as shown by the fact that
enforced expression of a Cul1 dominant-negative
mutant induces multiple centrosome abnormalities, not
only a failure of the centrioles to separate (Piva et al.,
2002). The FBP interacting with Cul1 and Skp1 to form
a centrosomal SCF complex is not known, and it is
actually possible that multiple SCF E3s, each containing
a different FBP, are involved in different phases of the
centrosomal cycle. So far, two genes encoding FBPs
(Skp2 and b-Trcp1) have been inactivated in mice and
both show overduplication of centrosomes (Nakayama
et al., 2000; Guardavaccaro et al., 2003). Skp2 deﬁciency
induces endoreduplication and inhibits the entry into
mitosis via a mechanism that is not yet understood.
Thus, centrosomal overduplication in Skp2/ cells
might be the result of a prolonged period spent in
S phase. In fact, the centrosome cycle is dissociated from
the cell division cycle since an arrest either at G1/S or in
mitosis does not block centrosomal duplication, hence
generating multiple centrosomes per cell (Gard et al.,
1990; Balczon et al., 1995). b-Trcp1 deﬁciency might
induce centrosomal overduplication by its ability to
delay mitosis progression by increasing Emi1 levels and
consequently inducing an inhibition of APC/CCdc20. In
agreement with this hypothesis, overexpression of Emi1
causes centrosomal overduplication. APC/C substrates,
such as Cyclin A, Aurora-A, Plk1, Cdc25A and Nek2,
stabilized as a result of APC/C inhibition by Emi1,
could play a role in the ampliﬁcation and separation of
centrosomes in the absence of b-Trcp1 function. Despite
the role of Skp2 in regulating the centrosomal cycle,
evidence that this protein is stably associated with the
centrosomes is lacking. In contrast, b-Trcp1 has been
recently found localized on the centrosomes by a mass
spectrometry-based proteomic analysis (Andersen et al.,
2003).
Cdl2 and Cdl5
In C. elegans, Cul2 functions as a positive cell cycle
regulator. It is expressed mainly in proliferating cells,
and disruption of Cul2 expression induces G1 arrest of
germ cells (Feng et al., 1999). This block correlates with
the accumulation of the CDK inhibitor Cki-1. Cul2 is
also necessary for proper movement of the cytoskeleton
and mitotic chromosome condensation. As with Cul1,
Cul2 is expected to bind a large number of substrate
receptor subunits given that a large number of SBPs and
BCBPs have been identiﬁed (Hilton et al., 1998; Kile
et al., 2002).
It has been shown that the product of the von Hippel–
Lindau (VHL) tumor suppressor gene interacts, via its
BC box, with Cul2, Elongin B, Elongin C and Roc1 to
form a Cdl2, also known as VBC complex (Kaelin,
2002). Various studies revealed that, under normoxic
conditions, Cdl2VHL targets the hypoxia-inducible factor
subunits HIF-1a and HIF-2a for ubiquitinylation and
degradation, shedding light on the cancer pathogenesis
of the VHL syndrome (Kondo et al., 2002; Maranchie
et al., 2002). The VHL disease is caused by germline
mutations of the VHL gene (Pugh and Ratcliffe, 2003).
Patients with VHL are predisposed to a variety of
tumors, including renal carcinomas, pheochromocyto-
mas, central nervous system hemangiosarcomas and
retinal angiomas. These tumors develop when the
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remaining wild-type allele is inactivated by deletions,
mutations or hypermethylation. Moreover, the majority
of sporadic renal clear cell carcinomas also display loss
of both VHL alleles. A hallmark of VHL-associated
neoplasms is their hypervascular nature due to the
constitutive expression of hypoxia-inducible genes,
like those encoding erythropoietin, vascular endo-
thelial growth factor and glucose transporter. In this
context, the identiﬁcation of the HIF-a complex as a
proteolytic target of the Cdl2VHL E3 ubiquitin ligase
provides a link between the ubiquitin–proteasome
system and the tumor suppressor activity of VHL.
Importantly, VHL mutants in C. elegans appear
indistinguishable from wild-type worms at normal
oxygen levels (ET Kipreos, personal communication)
indicating that the cell cycle phenotype observed in the
cul2 knockout is not due to the loss of VHL function.
These results suggest the presence of a different
substrate receptor in Cdl2 that is responsible for its cell
cycle functions.
Another BCBP, known as mediator subunit
Med8, has been shown to assemble with Cul2,
Elongin B and C, and Roc1, via its BC box to form
a complex recruiting ubiquitin ligase activity to the
RNA polymerase transcriptional machinery (Brower
et al., 2002).
The SOCS box domain is contained in more than 40
proteins belonging to different families, the canonical
SOCS family comprising Socs1–7 and the cytokine-
inducible SH2-containing proteins (CISs), the ankyrin
repeat proteins with a SOCS box (ASBs), the SPRY
domain proteins with a SOCS box (SSBs), the WD40
repeat proteins with a SOCS box (WSBs), the tubby
domain-containing proteins with a SOCS box (TSBs),
the Rar proteins and the Neuralized family of proteins
(Hilton et al., 1998). All these polypeptides contain,
besides the SOCS box, additional domains involved in
protein–protein interactions. Many of these, such as
Socs1, Socs3, Wsb1, Asb2 and Rar, have been shown to
associate with Elongin B and Elongin C (Kamura et al.,
1998), but demonstrations that these complexes interact
with Cullin2 and Roc1 and have ubiquitin ligase activity
are still missing for most of them.
Socs1, an Src homology 2 (SH2)-containing protein
that negatively controls cytokine and growth factor
signaling, interacts with Cul2, Elongin B and Elongin C
(De Sepulveda et al., 2000; Kamizono et al., 2001). This
complex has been found to function as a ubiquitin ligase
and promote ubiquitin-dependent degradation of Tel-
Jak2, a gene product found in human leukemia derived
from the fusion of the TEL gene to the JAK2 tyrosine
kinase gene. Moreover, overexpression of Socs1 can
efﬁciently suppress the transforming potential of Tel-
Jak2 (Kamizono et al., 2001). Cdl2Socs1 can also mediate
the ubiquitinylation and subsequent degradation of
the hematopoiesis-speciﬁc guanine nucleotide
exchange factor Vav, a human oncoprotein expressed
in hematopoietic cells (De Sepulveda et al., 2000).
Finally, Socs1 promotes the ubiquitinylation and
degradation of the insulin receptor substrates IRS1
and IRS2 (Rui et al., 2002).
It has been reported that besides Cul2, Cul5 is also
able to assemble with Roc1, Elongin B, Elongin C and a
BCBP to form a similar multiprotein complex with
ubiquitin ligase activity (Kamura et al., 2001). Several
SBPs and BCBPs have been shown to associate with
Cul5–Roc1–Elongin B–Elongin C: Muf-1, a leucine-rich
repeat containing protein, Socs1, Elongin A and WSB-1
(Kamura et al., 2001). The Cul5–Elongin B–Elongin C–
Roc1 complex can also interact with the two adenovirus
proteins E4orf6 and E1B55k (Querido et al., 2001a). It
was previously shown that these two proteins are able to
bind the tumor suppressor p53, inhibit its transcrip-
tional activity and induce its efﬁcient degradation
(Querido et al., 2001b). E4orf6 and E1B55k, bound to
the Cul5–Elongin B–Elongin C–Roc1 complex, are able
to induce p53 ubiquitinylation in vitro in the presence of
E1 and an E2. E4orf6/E1B55k-mediated degradation of
p53 is analogous to that induced by the human
papilloma virus (HPV) E6 oncoprotein, which recruits
the cellular ubiquitin ligase, E6-associated protein, to
p53, thereby targeting it for degradation (Pagano and
Benmaamar, 2003). Hence, in both cases, a viral
oncoprotein can associate with a cellular ubiquitin
ligase enzyme and use it to eliminate the tumor
suppressor p53.
Cdl3
In C. elegans, depletion of Cul3 by RNA interference
causes defects in early embryogenesis resulting in
abnormal microﬁlament and microtubule organization
(Kurz et al., 2002). Cul3 is also required for proper
development in mice since inactivation of the Cul3 locus
by homologous recombination results in embryonic
lethality prior to 7.5 days of gestation with defects both
in embryonic and extraembryonic compartments (Singer
et al., 1999). The extraembryonic tissues are completely
disorganized and the trophectoderm develops abnor-
mally. Gastrulation is also abnormal in Cul3-deﬁcient
embryos. In addition, increased levels of free (non-
Cdk2-associated) Cyclin E protein were observed in the
ectoplacental cone and extraembryonic ectoderm of
Cul3/ embryos (Singer et al., 1999). However, it is
unlikely that the early embryonic lethality of Cul3-
deﬁcient mice could be solely caused by a defective
degradation of a subpopulation of Cyclin E, and the
recent discovery that in C. elegans Cul3 interacts with
several BTBPs likely targeting a high number of
different substrates (see Introduction) is in favor of this
scenario. One of these BTBPs, Mel-26, binds to the
microtubule-severing protein Mei-1/katanin. Mei-1 is an
essential component of the C. elegans meiotic spindle.
Although the precise role of Mei-1 protein in the meiotic
spindle is unknown, it has been found that Mei-1 is
degraded at the meiosis to mitosis transition and that
Cul3 is required for its degradation. Moreover, loss-of-
function mutations of mel-26 result in Mei-1 protein
ectopically localized in mitotic spindles and centrosomes
leading to small and misoriented cleavage spindles and
arrest at the single-cell embryo stage (Dow and Mains,
1998). Moreover, loss-of-function mutations in mei-1
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fully suppress these defects (Kurz et al., 2002). Cul3
silencing by RNA interference results in abortive
cytokinesis and analogous spindle orientation defects
with misoriented spindles that become displaced toward
one pole (Kurz et al., 2002). These genetic results,
together with the ﬁnding that Mel-26 physically inter-
acts with Mei-1 (Furukawa et al., 2003; Geyer et al.,
2003; Pintard et al., 2003; Xu et al., 2003), strongly
indicate that a Cul3-dependent ubiquitin ligase, Cdl3Mel-
26, might target Mei-1 for degradation. However, a direct
biochemical assay demonstrating Mei-1 ubiquitinylation
by Cdl3Mel-26 is still missing. The discovery that Cul3 is
capable of associating with many adaptor proteins that
in turn recognize speciﬁc targets, together with the role
in oncogenesis played by other cullins, leads to the
speculation that Cdl3 might control the ubiquitinylation
and degradation of cancer-related proteins. In support
of this hypothesis, in the developing eye disc of D.
melanogaster, Cul3 controls the stability of Cubitus
interruptus (Ou et al., 2002), a major player of the
Hedgehog signaling pathway. This latter has been found
to be involved in the genesis of many different human
tumors, such as basal cell carcinomas, medulloblasto-
mas (Matise and Joyner, 1999), pancreatic adenocarci-
nomas (Thayer et al., 2003) and in various tumors of the
digestive tract (Berman et al., 2003).
Finally, S. pombe Cul3 interacts with the BTBP Btb3p
(Geyer et al., 2003), the ﬁssion yeast ortholog of human
Bpoz2, a protein that is thought to be implicated in the
growth arrest mediated by the tumor suppressor PTEN
(Unoki and Nakamura, 2001).
Cdl4
The gene encoding Cul4A is ampliﬁed in 16% of
primary breast cancers, and RNA in situ hybridization
analysis indicates that 47% of primary breast cancers
overexpress Cul4A (Chen et al., 1998). Moreover,
13q34, a chromosome region where CUL4A is mapped,
is frequently ampliﬁed in primary hepatocellular carci-
nomas (HCC) and in several other tumors including
primary esophageal squamous carcinomas (Yasui et al.,
2002). Accordingly, CUL4A shows ampliﬁcation and
consequent overexpression in certain primary HCC.
These ﬁndings suggest that Cul4A plays an important
role in tumorigenesis. Interestingly, Groisman et al.
(2003) have shown that Cul4A is involved in nucleotide
excision repair (NER), an essential cellular defense
mechanism against the oncogenic consequence of
ultraviolet light. They reported that two NER proteins,
known as DDB2 and CSA, are associated with identical
complexes containing Cul4A, Roc1, DDB1 and the
COP9 signalosome. These complexes display ubiquitin
activity that is regulated in response to UV irradiation.
Inhibition of the COP9 signalosome causes defects in the
NER process. However, it is still unclear if the DDB
proteins act as substrate recognition subunits or are
direct targets of Cdl4, since two groups found that
Cul4A induces ubiquitinylation of DDB2 and increases
its degradation (Chen et al., 2001; Nag et al., 2001).
Interestingly, DDB2 mutants have been identiﬁed from
patients affected by xeroderma pigmentosum, a disease
characterized by defective NER and predisposition to
skin cancer (Nag et al., 2001). DDB2 mutants are
characterized by a defect in the repair of UV-damaged
DNA, suggesting that abnormal expression of Cul4A
results in reduced DDB levels, thus impairing the ability
of DDB in repairing the DNA of tumor cells.
It has been shown that Cul4 has a role in maintaining
genomic stability by temporally restricting DNA repli-
cation licensing in C. elegans (Zhong et al., 2003).
Silencing of Cul4 by RNA interference leads to massive
DNA re-replication and S phase accumulation of the
replication-licensing factor Cdt1, which, at least in
mammals, could also be a target of Cul1 (see above).
It has been proposed that Cul4 functions in S phase to
degrade Cdt1 in order to prevent DNA re-replication.
All together, these results indicate that Cul4 plays an
important role in regulating DNA replication and
repair, and suggest a mechanism by which overexpres-
sion of Cul4A can contribute to tumor development.
Conclusions
Aberrant activities of many CDLs in human tumors
have been described. Undoubtedly, the coming years
promise a plethora of studies that will address how
defective or overactive protein degradation contributes
to tumor development. Furthermore, many crucial
protein substrates that play a major role in tumorigen-
esis are not yet linked to their speciﬁc ubiquitin ligases,
the identiﬁcation of which will provide valuable knowl-
edge for developing new therapeutic agents for cancer
treatment.
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